The Outcomes Research Program has the following four specific aims: 1) Evaluate the outcomes of cancer, including health-related quality of life, in a broad range of health care settings 2) Assess the effectiveness and costs of new &established interventions to prevent, detect and treat cancer 3) Identity determinants of the quality of cancer care 4) Characterize barriers to optimal care with a special focus on racial, ethnic and socioeconomic disparities in cancer care and approaches to eliminate disparities in care To achieve these objectives, the Program has assembled a multi-disciplinary group of investigators with demonstrated expertise in the methods of health services research and a proven commitment to the study of cancer outcomes. Their research spans the continuum from basic methodological studies, through clinical applications, to policy applications. The Program was originally funded in 2000 when Dana-Farber/Harvard Cancer Center was established, and it was rated as "outstanding" in the last renewal in 2005. The Program is led by J. Ayanian(BWH) and J.Weeks(DFCI) and currently has 54 members from 11 HMS departments and three HSPH departments with representation from all seven member institutions. In 2009, Program members were awarded $14.2 million in research funding (total costs), which includes over $9 million in NCI funding and $2.8 million in other federal peer-reviewed funding. The total number of publications from members of the Program during the project period (2006 to 2010) was 1,055. Ofthese 17% ofthese were intra-programmatic collaborations, 33% were inter-programmatic, and 24% were inter-institutional.
The Outcomes Research Program focuses on enhancing the effectiveness and cost-effectiveness of interventions to prevent, diagnose and treat cancer and its consequences. The primary focus is on evaluating interventions that optimize patient-oriented outcomes, identifying barriers to optimal care of all patients, defining approaches to eliminate these barriers, and ensuring that society's resources are allocated effectively to achieve those goals.
|Chen, Yi-Bin; Batchelor, Tracy; Li, Shuli et al. (2015) Phase 2 trial of high-dose rituximab with high-dose cytarabine mobilization therapy and high-dose thiotepa, busulfan, and cyclophosphamide autologous stem cell transplantation in patients with central nervous system involvement by non-Hodgkin lymphoma. Cancer 121:226-33|
|Waldron, Levi; Haibe-Kains, Benjamin; Culhane, Aedín C et al. (2014) Comparative meta-analysis of prognostic gene signatures for late-stage ovarian cancer. J Natl Cancer Inst 106:|
|Yilmazel, Bahar; Hu, Yanhui; Sigoillot, Frederic et al. (2014) Online GESS: prediction of miRNA-like off-target effects in large-scale RNAi screen data by seed region analysis. BMC Bioinformatics 15:192|
|Mazzola, Emanuele; Chipman, Jonathan; Cheng, Su-Chun et al. (2014) Recent BRCAPRO upgrades significantly improve calibration. Cancer Epidemiol Biomarkers Prev 23:1689-95|
|Zhao, Sihai Dave; Parmigiani, Giovanni; Huttenhower, Curtis et al. (2014) Más-o-menos: a simple sign averaging method for discrimination in genomic data analysis. Bioinformatics 30:3062-9|
|Parkhitko, Andrey A; Priolo, Carmen; Coloff, Jonathan L et al. (2014) Autophagy-dependent metabolic reprogramming sensitizes TSC2-deficient cells to the antimetabolite 6-aminonicotinamide. Mol Cancer Res 12:48-57|
|Cheng, Long; Desai, Jigar; Miranda, Carlos J et al. (2014) Human CFEOM1 mutations attenuate KIF21A autoinhibition and cause oculomotor axon stalling. Neuron 82:334-49|
|Akbay, Esra A; Moslehi, Javid; Christensen, Camilla L et al. (2014) D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice. Genes Dev 28:479-90|
|Brunner, Andrew M; Blonquist, Traci M; Sadrzadeh, Hossein et al. (2014) Population-based disparities in survival among patients with core-binding factor acute myeloid leukemia: a SEER database analysis. Leuk Res 38:773-80|
|Karamichos, D; Hutcheon, A E K; Rich, C B et al. (2014) In vitro model suggests oxidative stress involved in keratoconus disease. Sci Rep 4:4608|
Showing the most recent 10 out of 177 publications